Abstract:The loss of dopaminergic neurons of the nigrostriatal system underlies the onset of the typical motor symptoms of Parkinson's disease (PD). Lewy bodies (LB) and Lewy neurites (LN), proteinaceous inclusions mainly composed of insoluble α-synuclein (α-syn) fibrils are key neuropathological hallmarks of the brain of affected patients. Compelling evidence supports that in the early prodromal phases of PD, synaptic terminal and axonal alterations initiate and drive a retrograde degeneration process culminating with the loss of nigral dopaminergic neurons. This notwithstanding, the molecular triggers remain to be fully elucidated. Although it has been shown that α-syn fibrillary aggregation can induce early synaptic and axonal impairment and cause nigrostriatal degeneration, we still ignore how and why α-syn fibrillation begins. Nuclear factor-κB (NF-κB) transcription factors, key regulators of inflammation and apoptosis, are involved in the brain programming of systemic aging as well as in the pathogenesis of several neurodegenerative diseases. The NF-κB family of factors consists of five different subunits (c-Rel, p65/RelA, p50, RelB, and p52), which combine to form transcriptionally active dimers. Different findings point out a role of RelA in PD. Interestingly, the nuclear content of RelA is abnormally increased in nigral dopamine (DA) neurons and glial cells of PD patients. Inhibition of RelA exert neuroprotection against (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) MPTP and 1-methyl-4-phenylpyridinium (MPP+) toxicity, suggesting that this factor decreases neuronal resilience. Conversely, the c-Rel subunit can exert neuroprotective actions. We recently described that mice deficient for c-Rel develop a PD-like motor and non-motor phenotype characterized by progressive brain α-syn accumulation and early synaptic changes preceding the frank loss of nigrostriatal neurons. This evidence supports that dysregulations in this transcription factors may be involved in the onset of PD. This review highlights observations supporting a possible interplay between NF-κB dysregulation and α-syn pathology in PD, with the aim to disclose novel potential mechanisms involved in the pathogenesis of this disorder.

Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Alpha-Synuclein Aggregation in Parkinson's Disease

Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease

Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease

An Overview on the Role of Α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

Navigating the Neurobiology of Parkinson's: The Impact and Potential of α-Synuclein

α-Synuclein and Its Probable Mechanisms in Pathogenesis of Parkinson's Disease

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Alpha-Synuclein: The Interplay Of Pathology, Neuroinflammation, And Environmental Factors In Parkinson'S Disease

Protein–protein interactions regulating α-synuclein pathology

Epigenetic Modifications in Parkinson's Disease: A Critical Review

From Pathogenesis to Therapeutic Prospects

Ignored Avenues in Alpha-Synuclein Associated Proteopathy

Analysis of α-syn and parkin interaction in mediating neuronal death in Drosophila model of Parkinson's disease

Therapeutic potential of Parkin and its regulation in Parkinson's disease

The crucial role of VPS35 and SHH in Parkinson's disease: Understanding the mechanisms behind the neurodegenerative disorder

Key genes and convergent pathogenic mechanisms in Parkinson disease

Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease

Aggregation States of α-Synuclein and Its Involvement in Parkinson’s Disease

Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification